3.4.3. Effectiveness Phase 
SECONDARY, RECRUITMENT
A prospective randomized controlled single-blinded trial has been considered to estimate the efficacy of clinic-based versus home-based HPV self-sampling among HIV-infected women at the HIV clinic. As women came to the HIV clinic, they could prospectively be randomized to clinic-based or home-based HPV self-sampling. This would be a single-blinded randomized controlled trial, in which the study participants would not know the arm to which they had been assigned. After recruitment and consent, a randomization Excel list would be generated, and participants randomized to the two study arms in the ratio of 1:1. However, a random sample of HPV-positive women who took up HPV testing in both arms at baseline could also be subjected to VIA. The women would be followed up at 6 months, to measure their continued uptake rate of HPV self-sampling. The period of six months has been considered as is the time for their refill treatment for ART. As the study is tailored so that the findings could be used to design screening approaches that were public, feasible, and cost-effective, a modified societal perspective could be used to model the cost-effectiveness analysis. Non-medical costs would be obtained from the interviews that we conducted with the women, and from the secondary data analysis of the budgets. However, comparisons for the transport costs, personnel time, patient waiting time, and time spent in the facility would be considered. 